ACEDOBEN SODIUM

Details

Stereochemistry	ACHIRAL
Molecular Formula	C9H8NO3.Na
Molecular Weight	201.1545
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Na+].CC(=O)NC1=CC=C(C=C1)C([O-])=O

InChI

InChIKey=QCTHGBUDZUJILN-UHFFFAOYSA-M

InChI=1S/C9H9NO3.Na/c1-6(11)10-8-4-2-7(3-5-8)9(12)13;/h2-5H,1H3,(H,10,11)(H,12,13);/q;+1/p-1

HIDE SMILES / InChI

Molecular Formula	Na
Molecular Weight	22.9898
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C9H8NO3
Molecular Weight	178.1647
Charge	-1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.medicines.org.uk/emc/medicine/27089
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/2431857

Acedoben (4-acetamidobenzoic acid) is a benzoic acid derivative and a metabolite of benzocaine. It is a component of immunomodulatory drug inosine pranobex, which is used to treat mucocutaneous infections due to herpes simplex virus (type 1 and/or type II), genital warts as adjunctive therapy to podophyllin or carbon dioxide laser, and subacute sclerosing panencephalitis.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
immune response 6 Target ID: GO:0006955 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2431857	Modulator 828

Conditions

Condition	Modality	Highest Phase	Product
Herpes simplex infection 28 Sources: https://www.medicines.org.uk/emc/medicine/27089	Primary	Approved 8429	IMUNOVIR Approved Use Imunovir tablets are indicated in the management of mucocutaneous infections due to herpes simplex virus (type 1 and/or type II), genital warts as adjunctive therapy to podophyllin or carbon dioxide laser, and subacute sclerosing panencephalitis. Launch Date 1983
Genital warts 14 Sources: https://www.medicines.org.uk/emc/medicine/27089	Primary	Approved 8429	IMUNOVIR Approved Use Imunovir tablets are indicated in the management of mucocutaneous infections due to herpes simplex virus (type 1 and/or type II), genital warts as adjunctive therapy to podophyllin or carbon dioxide laser, and subacute sclerosing panencephalitis. Launch Date 1983
Subacute sclerosing panencephalitis 4 Sources: https://www.medicines.org.uk/emc/medicine/27089	Primary	Approved 8429	IMUNOVIR Approved Use Imunovir tablets are indicated in the management of mucocutaneous infections due to herpes simplex virus (type 1 and/or type II), genital warts as adjunctive therapy to podophyllin or carbon dioxide laser, and subacute sclerosing panencephalitis. Launch Date 1983

PubMed

Title	Date	PubMed
Design and synthesis of benzoic acid derivatives as influenza neuraminidase inhibitors using structure-based drug design.	1997 Dec 5	9406595
Ellagic acid inhibited 2-aminofluorene and p-aminobenzoic acid acetylation by mononuclear leucocytes from Sprague-Dawley rats.	2001	11258539
Toxicology and carcinogenesis studies of p-nitrotoluene (CAS no. 99-99-0) in F344/N rats and B6C3F(1) mice (feed studies).	2002 May	12118261
Metabolites of a blocked chloramphenicol producer.	2003 Jan	12542347
PCR and flow cytometric analysis of paclitaxel-inhibited arylamine N-acetyltransferase activity and gene expression in human osteogenic sarcoma cells (U-2 OS).	2004 Jan-Feb	15015580
Prognostic value of N-terminal pro-brain natriuretic peptide in elderly people with acute myocardial infarction: prospective observational study.	2009 May 6	19420032
Ambiguity aversion in rhesus macaques.	2010	20922060
Striatal BOLD Response Reflects the Impact of Herd Information on Financial Decisions.	2010	20589242
Immunomodulatory effects of inosine pranobex on cytokine production by human lymphocytes.	2015 Jun	26011933

Patents

Sample Use Guides

In Vivo Use Guide

Mucocutaneous herpes simplex: 1 g q.d.s. (4g daily), for 7 -14 days. Genital warts: 1g t.d.s. (3g daily), for 14-28 days as adjunctive therapy to podophyllin or carbon dioxide laser. Subacute sclerosing panencephalitis (SSPE): 50-100mg/kg daily, in divided does every 4 hours.

Route of Administration: Oral

In Vitro Use Guide

Inosine pranobex has been shown to stimulate various indices of metabolic activity of macrophages and monocytes. In vitro exposure to inosine pranobex or to 24-hour supernatants obtained from mononuclear cells pretreated with the drug restored chemotaxis to normal or near normal levels. Incubation with inosine pranobex in vitro stimulated the production of interleukin-l (lymphocyte activating factor) in human monocytes.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:46:36 GMT 2023` Edited by `admin` on `Fri Dec 15 15:46:36 GMT 2023`
Record UNII	IO8823D6X7
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ACEDOBEN SODIUM

Common Name

English

SODIUM 4-ACETAMIDOBENZOATE

Systematic Name

English

BENZOIC ACID, 4-(ACETYLAMINO)-, SODIUM SALT (1:1)

Common Name

English

SODIUM P-ACETAMIDOBENZOATE

Common Name

English

Acedoben Sodium [WHO-DD]

Common Name

English

BENZOIC ACID, 4-(ACETYLAMINO)-, SODIUM SALT

Common Name

English

SODIUM P-ACETYLAMINOBENZOATE

Common Name

English

Code System Code Type Description

DRUG BANK

DBSALT002366